Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma

Precision oncology requires sensitive and specific clinical biomarkers. Carbohydrate Antigen 19-9 (CA19-9) is widely used in pancreatic ductal adenocarcinoma (PDA) but lacks sensitivity and specificity. Nearly all PDAs harbor somatic KRAS mutations, nominating circulating tumor DNA (ctDNA) KRAS as an alternative disease biomarker, however, variable clinical performance has limited its clinical utility. We applied an ultrasensitive, PCR mutation enrichment, next generation sequencing ctDNA KRAS assay in a large cohort of patients with unresectable PDA (N = 189) recruited to the BIOPAC study between 2008–2015. Baseline and longitudinal serum CA19-9 and plasma ctDNA KRAS were correlated with time to progression (TTP) and overall survival (OS). Baseline ctDNA KRAS detection rate was 93.7% (86.4% in patients with non-elevated CA19-9). ctDNA KRAS and CA19-9 were positively correlated yet independently associated with TTP and OS (ctDNA KRAS p = 0.0018 and 0.0014; CA19-9 p = 0.0294 and 0.0007, respectively). A generated model quantitating longitudinal ctDNA KRAS correctly assessed greater than 80% of patient responses. Quantitative detection of KRAS ctDNA is an informative prognostic biomarker, complementary to CA19-9 in patients with unresectable PDA. Longitudinal ctDNA KRAS may inform therapeutic decision making and provides a kinetically dynamic and quantitative metric of patient response.

[1]  E. Petricoin,et al.  A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative , 2016, Oncotarget.

[2]  M. Erlander,et al.  Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers , 2017, Clinical Cancer Research.

[3]  Valérie Taly,et al.  Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker , 2016, Clinical Cancer Research.

[4]  O. von Ahsen,et al.  Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer. , 2016, Clinical chemistry.

[5]  M. Erlander,et al.  A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  J. Berlin,et al.  Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials: A Systematic Review. , 2016, JAMA oncology.

[7]  J. Søreide,et al.  Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer , 2016, Molecular oncology.

[8]  F. Cardoso,et al.  The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review , 2015, Breast Cancer Research.

[9]  B. Sands,et al.  Genetics, Genetic Testing, and Biomarkers of Digestive Diseases. , 2015, Gastroenterology.

[10]  Beatriz Bellosillo,et al.  Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.

[11]  Michael A. Choti,et al.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets , 2015, Nature Communications.

[12]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[13]  B. Chan,et al.  Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. , 2015, Translational lung cancer research.

[14]  V. Velculescu,et al.  Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. , 2014, Cancer discovery.

[15]  M. Ando,et al.  Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction. , 2014, Clinical lung cancer.

[16]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[18]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[19]  C. Galli,et al.  CA 19-9: handle with care , 2013, Clinical chemistry and laboratory medicine.

[20]  B. Dörken,et al.  Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy , 2013, Front. Oncol..

[21]  S. Bojesen,et al.  MicroRNA biomarkers in whole blood for detection of pancreatic cancer. , 2013, JAMA.

[22]  P. Philip,et al.  Carbohydrate antigen 19‐9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine‐containing chemotherapy , 2013, Cancer.

[23]  U. Ballehaninna,et al.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. , 2012, Journal of gastrointestinal oncology.

[24]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[25]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[26]  Z. Meng,et al.  K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  J. Marshall,et al.  Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents , 2010, Gastrointestinal cancer research : GCR.

[28]  P. Philip,et al.  CA19‐9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy , 2010, Asia-Pacific journal of clinical oncology.

[29]  Derrick Wong,et al.  Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy , 2008, Pancreas.

[30]  W. Scheithauer,et al.  CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. , 2008, The Lancet. Oncology.

[31]  for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[32]  M. Tempero,et al.  Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer , 2005, British Journal of Cancer.

[33]  H. Oettle,et al.  Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes , 2005, British Journal of Cancer.

[34]  T. Sauerbruch,et al.  Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine , 2003, British Journal of Cancer.

[35]  J. Yu,et al.  A Prospective Study of Detection of Pancreatic Carcinoma by Combined Plasma K -ras Mutations and Serum CA19-9 Analysis , 2002, Pancreas.

[36]  P. Ruszniewski,et al.  Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA , 2002, British Journal of Cancer.

[37]  V. Keim,et al.  Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer , 2000, British Journal of Cancer.

[38]  G. Capellá,et al.  K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M Monden,et al.  Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  M. Farthing,et al.  A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  D. Pleskow,et al.  Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. , 1989, Annals of internal medicine.

[42]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[43]  H. Aste,et al.  CA 19‐9 and CA 50 in Benign and malignant pancreatic and biliary diseases , 1988, Cancer.

[44]  M. Tempero,et al.  Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. , 1987, Cancer research.

[45]  B. Shapiro,et al.  Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease , 1983, Cancer.

[46]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[47]  P Mandel,et al.  Les acides nucleiques du plasma sanguin chez l' homme , 1948 .

[48]  S. Yachida,et al.  Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer. , 2016, Advances in experimental medicine and biology.

[49]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.

[50]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[51]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[52]  A. Nakao,et al.  Detection of K-ras mutations in the plasma DNA of pancreatic cancer patients , 2003, Journal of Gastroenterology.

[53]  A. Zerbi,et al.  Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. , 1987, Gastroenterology.